Legend Biotech Corporation: Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Legend Biotech (NASDAQ: LEGN) reported second-quarter 2026 results. CARVYKTI net trade sales rose 50% year over year to about $657 million, with U.S. up 32% and ex-U.S. up 128%. The company launched CARVYKTI in Ireland. It reported first-in-human LB2501 data (100% ORR, 83.3% CR at DL2) and raised about $212 million net from a public ADS offering. Cash and time deposits were about $965 million as of June 30, 2026.
How this was made
The 30-second read
Why it matters
This release is a combined commercial update (CARVYKTI growth and new market launch), pipeline validation (LB2501 first-in-human readout), and balance-sheet reinforcement (completed ADS offering and stated cash runway).
Market read
Traders can reassess near-term valuation drivers around CARVYKTI demand, the credibility of the in vivo CAR-T platform from LB2501, and funding runway after the ADS raise.
What to watch
The financials emphasize collaboration and milestone-driven revenue; investors may focus on whether future milestones under Janssen and other agreements remain on track, and how increased selling and distribution costs affect margins.
Background
Legend Biotech is a cell-therapy company with CARVYKTI (cilta-cel) commercialized and a pipeline including in vivo CAR-T programs such as LB2501 and DLL3-targeted LB2102.
Ticker impact
Legend Biotech reported Q2 2026 results, with CARVYKTI net trade sales up 50% to about $657M and a $212M ADS offering.
Near-term upside bias on improved growth visibility and balance-sheet reinforcement, with volatility tied to how investors value LB2501 and ongoing CARVYKTI durability.
The article discloses multiple concrete, decision-relevant items: reported sales growth, a new market launch, first-in-human efficacy/safety readout for LB2501, and a completed equity raise with stated net proceeds and cash runway.
Market effects
Reinforces investor appetite for CAR-T and in vivo CAR-T platforms, potentially supporting sentiment for cell-therapy peers with similar commercialization and pipeline narratives.
Ireland launch expands European access, which can marginally improve regional revenue expectations for CARVYKTI in Europe.
Global site and market expansion plus early pipeline readouts can influence broader expectations for next-generation CAR-T adoption worldwide.
Counterpoint
LB2501 is early proof-of-concept with small patient counts, so the market may over-discount the durability and scalability of efficacy and safety until later trials.
Key entities
- companyLegend Biotech Corporation
Reported Q2 2026 unaudited results and corporate highlights, including CARVYKTI growth, LB2501 first-in-human data, and a $212M ADS offering.
- productCARVYKTI (cilta-cel)
Commercial CAR-T therapy; net trade sales increased 50% YoY to about $657M in Q2 2026 and expanded to Ireland.
- investigational therapyLB2501
In vivo CD19/CD20 dual-targeting CAR-T; first-in-human proof-of-concept reported with 100% ORR and 83.3% CR at DL2.
- investigational therapyLB2102
DLL3-targeted CAR-T; first-in-human data for relapsed/refractory SCLC and LCNEC reported with ORR 28.6% at higher dose levels.
- executiveAlan Bash
Appointed Interim CEO, previously President of CARVYKTI.
